Shu-Qun Cheng (Shuqun Cheng)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 32

Top Venues

Hepatology international

Nature medicine

The oncologist

Hepatology (Baltimore, Md.)

This page only lists publications with an associated author ORCID identifier.

Publications

Lei Wang, Jin-Kai Feng, Chong-De Lu, Jia-Yi Wu, Bin Zhou, Kang Wang, Xu-Biao Wei, Chao Liang, Hong-Kun Zhou, Jie Shi, Wei-Xing Guo, Wan Yee Lau, Mao-Lin Yan, Shu-Qun Cheng
Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody. The oncologist 29 (8) (2024)
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Ying-Yi Qin, Jie Shi, Wei-Xing Guo, Chong-De Lu, Ya-Xin Zheng, Fei-Guo Zhou, Mao-Lin Yan, Hong-Kun Zhou, Chao Liang, Fan Zhang, Wen-Jing Wei, Wan Yee Lau, Jing-Jing Li, Yan-Fang Liu, Shu-Qun Cheng
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature medicine 30 (3) (2024)
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Ying-Yi Qin, Jie Shi, Wei-Xing Guo, Chong-De Lu, Ya-Xin Zheng, Fei-Guo Zhou, Mao-Lin Yan, Hong-Kun Zhou, Chao Liang, Fan Zhang, Wen-Jing Wei, Wan Yee Lau, Jing-Jing Li, Yan-Fang Liu, Shu-Qun Cheng
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature medicine 30 (3) (2024)
Xu Wang, Jin-Kai Feng, Fei-Fei Mao, Yu-Chao Hou, Yu-Qing Zhang, Li-Heng Liu, Qian Wei, Ju-Xian Sun, Chang Liu, Jie Shi, Shu-Qun Cheng
Prognostic and Immunotherapeutic Predictive Value of CAD Gene in Hepatocellular Carcinoma: Integrated Bioinformatics and Experimental Analysis. Molecular biotechnology (2024)
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Ying-Yi Qin, Jie Shi, Wei-Xing Guo, Chong-De Lu, Ya-Xin Zheng, Fei-Guo Zhou, Mao-Lin Yan, Hong-Kun Zhou, Chao Liang, Fan Zhang, Wen-Jing Wei, Wan Yee Lau, Jing-Jing Li, Yan-Fang Liu, Shu-Qun Cheng
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature medicine (2024)
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Ying-Yi Qin, Jie Shi, Wei-Xing Guo, Chong-De Lu, Ya-Xin Zheng, Fei-Guo Zhou, Mao-Lin Yan, Hong-Kun Zhou, Chao Liang, Fan Zhang, Wen-Jing Wei, Wan Yee Lau, Jing-Jing Li, Yan-Fang Liu, Shu-Qun Cheng
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature medicine 30 (3) (2024)
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Ying-Yi Qin, Jie Shi, Wei-Xing Guo, Chong-De Lu, Ya-Xin Zheng, Fei-Guo Zhou, Mao-Lin Yan, Hong-Kun Zhou, Chao Liang, Fan Zhang, Wen-Jing Wei, Wan Yee Lau, Jing-Jing Li, Yan-Fang Liu, Shu-Qun Cheng
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature medicine (2024)
Lei Wang, Jin-Kai Feng, Chong-De Lu, Jia-Yi Wu, Bin Zhou, Kang Wang, Xu-Biao Wei, Chao Liang, Hong-Kun Zhou, Jie Shi, Wei-Xing Guo, Wan Yee Lau, Mao-Lin Yan, Shu-Qun Cheng
Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody. The oncologist 29 (8) (2024)
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Ying-Yi Qin, Jie Shi, Wei-Xing Guo, Chong-De Lu, Ya-Xin Zheng, Fei-Guo Zhou, Mao-Lin Yan, Hong-Kun Zhou, Chao Liang, Fan Zhang, Wen-Jing Wei, Wan Yee Lau, Jing-Jing Li, Yan-Fang Liu, Shu-Qun Cheng
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature medicine (2024)
Lei Wang, Jin-Kai Feng, Chong-De Lu, Jia-Yi Wu, Bin Zhou, Kang Wang, Xu-Biao Wei, Chao Liang, Hong-Kun Zhou, Jie Shi, Wei-Xing Guo, Wan Yee Lau, Mao-Lin Yan, Shu-Qun Cheng
Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody. The oncologist (2024)
Shi-Ye Yang, Jin-Kai Feng, Mao-Lin Yan, Lei Guo, Yun-Fei Duan, Jia-Zhou Ye, Zong-Han Liu, Yan-Jun Xiang, Li Xu, Jie Xue, Jie Shi, Wan Yee Lau, Shu-Qun Cheng, Wei-Xing Guo
Laparoscopic and open liver resection for hepatocellular carcinoma with type 2 diabetes mellitus: multicenter propensity score-matched study. Hepatology international (2023)
Yi-Ping Tao, Heng-Yan Zhu, Qian-Yuan Shi, Cai-Xia Wang, Yu-Xin Hua, Han-Yin Hu, Qi-Yin Zhou, Zi-Lu Zhou, Ying Sun, Xiao-Min Wang, Yu Wang, Ya-Ling Zhang, Yan-Jun Guo, Zi-Ying Wang, Xuan Che, Chun-Wei Xu, Xian-Chao Zhang, Michal Heger, Su-Ping Tao, Xin Zheng, Ying Xu, Lei Ao, Ai-Jun Liu, Sheng-Bing Liu, Shu-Qun Cheng, Wei-Wei Pan
S1PR1 regulates ovarian cancer cell senescence through the PDK1-LATS1/2-YAP pathway. Oncogene (2023)
Siqi Li, Kun Li, Kang Wang, Haoyuan Yu, Xiangyang Wang, Mengchen Shi, Zhixing Liang, Zhou Yang, Yongwei Hu, Yang Li, Wei Liu, Hua Li, Shu-Qun Cheng, Linsen Ye, Yang Yang
Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8 + exhausted-like T cells. Nature communications 14 (1) (2023)
Hong-Ming Yu, Kang Wang, Jin-Kai Feng, Lei Lu, Yu-Chen Qin, Yu-Qiang Cheng, Wei-Xing Guo, Jie Shi, Wen-Ming Cong, Wan Yee Lau, Hui Dong, Shu-Qun Cheng
Image-matching digital macro-slide-a novel pathological examination method for microvascular invasion detection in hepatocellular carcinoma. Hepatology international 16 (2) (2022)
Lei Guo, Xubiao Wei, Shuang Feng, Jian Zhai, Weixing Guo, Jie Shi, Wan Yee Lau, Yan Meng, Shu-Qun Cheng
Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial. Hepatology international 16 (6) (2022)
Bao-Qian Shan, Xiao-Min Wang, Li Zheng, Yao Han, Jie Gao, Meng-Dan Lv, Yi Zhang, Yi-Xuan Liu, Han Zhang, Hao-Sa Chen, Lei Ao, Yin-Li Zhang, Xiang Lu, Zhong-Jie Wu, Ying Xu, Xuan Che, Michal Heger, Shu-Qun Cheng, Wei-Wei Pan, Xin Zhang
DCAF13 promotes breast cancer cell proliferation by ubiquitin inhibiting PERP expression. Cancer science 113 (5) (2022)
Liu-Qing Yang, Han-Yin Hu, Yao Han, Ze-Yi Tang, Jie Gao, Qi-Yin Zhou, Yi-Xuan Liu, Hao-Sa Chen, Tu-Nan Xu, Lei Ao, Ying Xu, Xuan Che, Ya-Bo Jiang, Chun-Wei Xu, Xian-Chao Zhang, Yu-Xin Jiang, Michal Heger, Xiao-Min Wang, Shu-Qun Cheng, Wei-Wei Pan
CpG-binding protein CFP1 promotes ovarian cancer cell proliferation by regulating BST2 transcription. Cancer gene therapy (2022)
Kang Wang, Yanjun Xiang, Jiangpeng Yan, Yuyao Zhu, Hanbo Chen, Hongming Yu, Yuqiang Cheng, Xiu Li, Wei Dong, Yan Ji, Jingjing Li, Dong Xie, Wan Yee Lau, Jianhua Yao, Shu-Qun Cheng
A deep learning model with incorporation of microvascular invasion area as a factor in predicting prognosis of hepatocellular carcinoma after R0 hepatectomy. Hepatology international 16 (5) (2022)
Shi-Ye Yang, Mao-Lin Yan, Yun-Fei Duan, Jin-Kai Feng, Jia-Zhou Ye, Yan-Jun Xiang, Zong-Han Liu, Lei Guo, Jie Xue, Shu-Qun Cheng, Wei-Xing Guo
Perioperative and long-term survival outcomes of laparoscopic versus laparotomic hepatectomy for BCLC stages 0-A hepatocellular carcinoma patients associated with or without microvascular invasion: a multicenter, propensity score matching analysis. Hepatology international 16 (4) (2022)
Zhen-Hua Chen, Xiu-Ping Zhang, Jin-Kai Feng, Le-Qun Li, Fan Zhang, Yi-Ren Hu, Cheng-Qian Zhong, Jie Shi, Wei-Xing Guo, Meng-Chao Wu, Wan Yee Lau, Shu-Qun Cheng
Actual long-term survival in hepatocellular carcinoma patients with microvascular invasion: a multicenter study from China. Hepatology international 15 (3) (2021)
Er-Bin Zhang, Xiuping Zhang, Kang Wang, Fengkun Zhang, Tian-Wei Chen, Ning Ma, Qian-Zhi Ni, Yi-Kang Wang, Qian-Wen Zheng, Hui-Jun Cao, Ji Xia, Bing Zhu, Sheng Xu, Xufen Ding, Xiang Wang, Zhigang Li, Shu-Qun Cheng, Dong Xie, Jing-Jing Li
Antifungal agent Terbinafine restrains tumor growth in preclinical models of hepatocellular carcinoma via AMPK-mTOR axis. Oncogene 40 (34) (2021)
Juxian Sun, Jiayi Wu, Chang Liu, Jie Shi, Yonggang Wei, Jianyin Zhou, Zhibo Zhang, Wan Yee Lau, Mao-Lin Yan, Shu-Qun Cheng
Typing of biliary tumor thrombus influences the prognoses of patients with hepatocellular carcinoma. Cancer biology & medicine (2021)
Qian-Zhi Ni, Zhenhua Chen, Qianwen Zheng, Dong Xie, Jing-Jing Li, Shu-Qun Cheng, Xingyuan Ma
Epithelial V-like antigen 1 promotes hepatocellular carcinoma growth and metastasis via the ERBB-PI3K-AKT pathway. Cancer science 111 (5) (2020)
Min Li, Xuxiao He, Weixing Guo, Hongming Yu, Shicheng Zhang, Ningning Wang, Guijun Liu, Rina Sa, Xia Shen, Yabo Jiang, Yufu Tang, Yujuan Zhuo, Chunzhao Yin, Qiaochu Tu, Nan Li, Xiaoqun Nie, Yu Li, Zhimin Hu, Hanwen Zhu, Jianping Ding, Zi Li, Te Liu, Fan Zhang, He Zhou, Shengxian Li, Jiang Yue, Zheng Yan, Shu-Qun Cheng, Yongzhen Tao, Hui-Yong Yin
Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways. Nature cancer 1 (7) (2020)
Xue Feng, Tiantian Lu, Jinhui Li, Ruizeng Yang, Liqiao Hu, Yi Ye, Feifei Mao, Lingli He, Jinjin Xu, Zuoyun Wang, Yingbin Liu, Yonglong Zhang, Hongbin Ji, Yun Zhao, Shu-Qun Cheng, Wei Tian, Lei Zhang
The Tumor Suppressor Interferon Regulatory Factor 2 Binding Protein 2 Regulates Hippo Pathway in Liver Cancer by a Feedback Loop in Mice. Hepatology (Baltimore, Md.) 71 (6) (2020)
Yabo Jiang, Yongzhen Tao, Xiuping Zhang, Xubiao Wei, Min Li, Xuxiao He, Bin Zhou, Weixing Guo, Huiyong Yin, Shu-Qun Cheng
Loss of STAT5A promotes glucose metabolism and tumor growth through miRNA-23a-AKT signaling in hepatocellular carcinoma. Molecular oncology 15 (2) (2020)
Xiu-Ping Zhang, Yu-Zhen Gao, Zhen-Hua Chen, Shu-Qun Cheng
Reply. Hepatology (Baltimore, Md.) 70 (5) (2020)
Shu-Qun Cheng, Xubiao Wei, Jie Shi, Weixing Guo, Shuang Feng, Jian Zhai, Bin Huang
A Multidisciplinary Team Approach to the Management of Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. The oncologist 25 (6) (2020)
Zhen-Hua Chen, Xiu-Ping Zhang, Yu-Gang Lu, Le-Qun Li, Min-Shan Chen, Tian-Fu Wen, Wei-Dong Jia, Dong Zhou, Jing Li, Ding-Hua Yang, Zuo-Jun Zhen, Yi-Jun Xia, Rui-Fang Fan, Yang-Qing Huang, Yu Zhang, Xiao-Jing Wu, Yi-Ren Hu, Yu-Fu Tang, Jian-Hua Lin, Fan Zhang, Cheng-Qian Zhong, Wei-Xing Guo, Jie Shi, Joseph Lau, Shu-Qun Cheng
Actual long-term survival in HCC patients with portal vein tumor thrombus after liver resection: a nationwide study. Hepatology international 14 (5) (2020)
Xiu-Ping Zhang, Kang Wang, Xu-Biao Wei, Le-Qun Li, Hui-Chuan Sun, Tian-Fu Wen, Zong-Tao Chai, Zhen-Hua Chen, Jie Shi, Wei-Xing Guo, Dong Xie, Wen-Ming Cong, Meng-Chao Wu, Wan Yee Lau, Shu-Qun Cheng
An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After R0 Liver Resection: A Large-Scale, Multicenter Study. The oncologist 24 (12) (2019)
Jie Shi, Juxian Sun, Chang Liu, Zongtao Chai, Nanya Wang, Hui Zhang, Shu-Qun Cheng
All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controlled trial. Trials 20 (1) (2019)
Xiu-Ping Zhang, Yu-Zhen Gao, Zhen-Hua Chen, Min-Shan Chen, Le-Qun Li, Tian-Fu Wen, Li Xu, Kang Wang, Zong-Tao Chai, Wei-Xing Guo, Jie Shi, Dong Xie, Meng-Chao Wu, Wan Yee Lau, Shu-Qun Cheng
An Eastern Hepatobiliary Surgery Hospital/Portal Vein Tumor Thrombus Scoring System as an Aid to Decision Making on Hepatectomy for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: A Multicenter Study. Hepatology (Baltimore, Md.) 69 (5) (2019)

Shu-Qun Cheng.css-eqlu8i{font-size:small;padding-left:4px;} (Shuqun Cheng)

Publication Activity (10 Years)

Top Topics

Top Venues

Shu-Qun Cheng (Shuqun Cheng)